Zealand Pharma in lucrative deal with Switzerland's Helsinn Healthcare  

Zealand Pharma is entering a partnering agreement with Helsinn Healthcare to develop and commercialize ZP1846 for the treatment of chemotherapy-induced diarrhoea
Danish biotech firm Zealand Pharma has announced in a press release that it is entering a partnering agreement with Swiss firm Helsinn Healthcare to develop and globally commercialize its drug candidate ZP1846 for the treatment of chemotherapy-induced diarrhoea.
The deal gives Helsinn Healthcare, which will handle all further development, exclusive licensing rights to ZP1846. In return Zealand Pharma will receive milestone payments and royalties on future sales. The total value of the non-royalty portion of the partnership is valued up to EUR 140m (USD 177m).
ZP1846 is a GLP-2 (glucagon-like peptide-2) receptor agonist which the company says provides a novel way to treat chemotherapy-induced diarrhoea, which affects up to 50% of patients undergoing certain forms of chemotherapy.
Dr. David Solomon, CEO of Zealand Pharma, comments in the press release: “We are delighted to be able to work with Helsinn Healthcare on the development and commercialization of ZP1846. Helsinn Healthcare is in a process to build a very strong worldwide presence in the cancer supportive care treatment area where ZP1846 will be an important product to ameliorate the destructive effects of the chemotherapy on the small intestine and reduce the severity of diarrhoea”.
Zealand Pharma focuses on the discovery and development of peptide-based drugs. The company writes on its website that its pipeline includes one compound in phase III clinical development, two compounds in phase II, and three compounds in phase I. Based in Copenhagen and employing 65 people, Zealand Pharma has existing clinical development partnerships with Sanofi-Aventis and Wyeth.
Link > Zealand Pharma         

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×